Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vaccination halts tumour growth in rhinos
white rhino
“If the oestrous cycle of female rhinoceros can be interrupted by a simple inoculation and, later on, fertility can recover again, the vaccination is a huge veterinary advance."
Improvac reduced size of innocuous tumour, scientists report

For the first time a vaccination has successfully stopped the growth and regeneration of innocuous tumours in rhinos, researchers say.

Southern white rhinos and greater one-horned rhinos were injected with the ‘Improvac’ serum, which affects the release of hormones and causes the female oestrus cycle to cease, thereby reducing hormone-dependent tumours.

Three months after the vaccination, scientists say ultrasound examination showed a reduction in tumour size to half its original size. And after a year, no more new growths were detected. The findings have been published in the journal PLOS ONE.

Female rhinos often suffer from vaginal or uterus tumours which complicate the process of reproduction. Whilst they are largely innocuous, if they grow too much the animal may have reduced fertility, or become completely infertile. Tumours can cause pain during mating and lead to problems with conception, as well as miscarriages and stillborns. However, it is not possible to cut out large tumours owing to the rhino’s thick skin.

Improvac is a hormone that relates to the body’s gonadotrophin-releasing hormone (GnRH), which regulates the release of sexual hormones from the hypophysis and, therefore, ovulation and ovarian activity.

After vaccination, antibodies are produced that block GnRH so the hypophysis stops releasing sexual hormones and the oestrus cycle and female fertility cease. As a result, scientists say hormone-dependent tumours stop growing and reduce in size.

Tumour risk is linked to whether or not rhinos have previously had offspring. Gestation at an early age prevents reproductive organs from forming tumours and existing tumours stop growing when an animal gets pregnant. As a result, researchers from the Leibniz Institute for Zoo and Wildlife Research believe early reproduction of rhinos should be promoted.

Robert Hermes, an expert in reproductive medicine and rhinos from the institute, said: “If they are not able to have offspring because of external circumstances, for instance in the absence of an available mate, a vaccination could help prevent tumour formation.

“The sexual cycle is put ‘on ice’ and can be reactivated for pregnancy later on without loss of the female’s fertility or the risk of tumours.”

Further study will be needed to determine whether the vaccine’s effects are completely reversible. The same treatment has already been successfully used in horse mares, who became fertile again with a normal sexual cycle some time after vaccination.

Hermes continued: “If the oestrous cycle of female rhinoceros can be interrupted by a simple inoculation and, later on, fertility can recover again, the vaccination is a huge veterinary advance. This is a great benefit, particularly with regard to the future health care management of rhinos in human care.”

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.